Molbio Diagnostics Ltd

AI

Molbio Diagnostics Ltd

₹ 1,438 -4.72%
11 Sep - close price
About

Molbio Diagnostics is an innovative point-
of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within
an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.

Through its wholly owned subsidiary,
Bigtec Labs, Molbio has strong research
and development capabilities focused on creating diagnostic platforms for point-of-
care (POC) testing. From product development to large-scale deployment, the company aims
to improve access to reliable and affordable healthcare for everyone.
https://www.molbiodiagnostics.com/wp-content/uploads/2026/08/Molbio-Diagnostics-Limited-Red-Herring-Prospectus.pdf#page=215 #}

  • Market Cap 16,574 Cr.
  • Current Price 1,438
  • High / Low 1,687 / 926
  • Stock P/E 66.4
  • Book Value
  • Dividend Yield 0.00 %
  • ROCE 18.5 %
  • ROE 15.6 %
  • Face Value 1.00

Pros

  • Company's working capital requirements have reduced from 148 days to 116 days

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2025 Mar 2026 Jun 2026
100 561 408
116 402 308
Operating Profit -16 159 101
OPM % -16% 28% 25%
1 5 3
Interest 4 12 11
Depreciation 12 20 17
Profit before tax -31 132 76
Tax % -23% 27% 31%
-24 96 53
EPS in Rs -10.51 8.06 5.21
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
837 1,020 1,446
602 760 1,126
Operating Profit 234 260 320
OPM % 28% 26% 22%
-49 -4 9
Interest 14 18 33
Depreciation 41 45 64
Profit before tax 130 194 231
Tax % 36% 29% 29%
84 139 164
EPS in Rs 452.37 64.34 14.77
Dividend Payout % 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 42%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 10%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 16%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Equity Capital 2 2 11
Reserves 821 966 1,158
184 147 450
211 346 496
Total Liabilities 1,218 1,461 2,115
289 290 536
CWIP 2 27 11
Investments 6 46 6
921 1,099 1,562
Total Assets 1,218 1,461 2,115

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
10 287 50
-45 -123 -54
-32 -26 276
Net Cash Flow -67 138 273
Free Cash Flow -7 232 1
CFO/OP 23% 141% 38%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Debtor Days 186 97 103
Inventory Days 338 384 285
Days Payable 101 203 126
Cash Conversion Cycle 423 278 261
Working Capital Days 200 128 116
ROCE % 21% 18%

Shareholding Pattern

Numbers in percentages

10 Recently
Aug 2026
41.29%
1.51%
16.36%
0.02%
40.83%
No. of Shareholders 2,33,544

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents